JP2014505736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505736A5 JP2014505736A5 JP2013554661A JP2013554661A JP2014505736A5 JP 2014505736 A5 JP2014505736 A5 JP 2014505736A5 JP 2013554661 A JP2013554661 A JP 2013554661A JP 2013554661 A JP2013554661 A JP 2013554661A JP 2014505736 A5 JP2014505736 A5 JP 2014505736A5
- Authority
- JP
- Japan
- Prior art keywords
- abuse
- pharmaceutical formulation
- total amount
- abuse deterrent
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 18
- 230000003113 alkalizing effect Effects 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 13
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 10
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 claims description 10
- 150000005846 sugar alcohols Polymers 0.000 claims description 10
- -1 beadlets Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229960003194 meglumine Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 229940005483 opioid analgesics Drugs 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- 229960002085 oxycodone Drugs 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 229960002900 methylcellulose Drugs 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443966P | 2011-02-17 | 2011-02-17 | |
| US61/443,966 | 2011-02-17 | ||
| PCT/US2012/025737 WO2012112952A1 (en) | 2011-02-17 | 2012-02-17 | Technology for preventing abuse of solid dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014505736A JP2014505736A (ja) | 2014-03-06 |
| JP2014505736A5 true JP2014505736A5 (cg-RX-API-DMAC7.html) | 2015-04-09 |
Family
ID=45932490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554661A Pending JP2014505736A (ja) | 2011-02-17 | 2012-02-17 | 固体投薬形態の乱用を防止するための技術 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120321716A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2675436A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014505736A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103476401A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012219322A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013021026A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2827273A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL227962A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013009492A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012112952A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| SI2456424T1 (sl) | 2009-07-22 | 2013-10-30 | Gruenenthal Gmbh | Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo |
| AR077493A1 (es) | 2009-07-22 | 2011-08-31 | Gruenenthal Gmbh | Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion |
| US20120321674A1 (en) * | 2011-02-17 | 2012-12-20 | Michael Vachon | Technology for Preventing Abuse of Solid Dosage Forms |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
| JP2014524925A (ja) | 2011-07-29 | 2014-09-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
| EP2736497B1 (en) * | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| MX349725B (es) * | 2011-11-17 | 2017-08-10 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o aversivo opioide, oxido de polialquileno y un polimero anionico. |
| FR2983409B1 (fr) * | 2011-12-06 | 2013-12-27 | Ethypharm Sa | Comprime susceptible de lutter contre le detournement par voie injectable |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| AU2013204592A1 (en) * | 2012-04-09 | 2013-10-24 | QRxPharma Ltd. | Controlled release formulations of opioids |
| AR090695A1 (es) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis |
| CA2864738C (en) | 2012-04-18 | 2017-07-18 | Mallinckrodt Llc | Immediate release, abuse deterrent pharmaceutical compositions |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| NZ704011A (en) | 2012-07-06 | 2016-04-29 | Egalet Ltd | Abuse deterrent pharmaceutical compositions for controlled release |
| PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
| US9226290B2 (en) | 2012-08-16 | 2015-12-29 | Qualcomm Incorporated | Multiple timing advance groups (TAGS) for UL carrier aggregation (CA) |
| PE20151301A1 (es) * | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| PL2968182T3 (pl) | 2013-03-15 | 2018-10-31 | SpecGx, LLC | Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem |
| MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
| EP3062777A2 (en) * | 2013-10-31 | 2016-09-07 | Cima Labs Inc. | Abuse-deterrent dosage forms |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN106061471A (zh) * | 2014-02-17 | 2016-10-26 | 赢创罗姆有限公司 | 具有持续释放特性并针对乙醇的影响具有抗性的药物或营养组合物 |
| MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
| MX2016015417A (es) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticulas protegidas contra vertido de dosis etanolico. |
| US11617712B2 (en) | 2014-07-03 | 2023-04-04 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| HK1223837A1 (zh) * | 2014-07-15 | 2017-08-11 | 艾萨．欧蒂迪 | 减少过剂量的组合物和方法 |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
| CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| WO2017059374A1 (en) * | 2015-09-30 | 2017-04-06 | Kashiv Pharma Llc | Overdose protection and abuse deterrent immediate release drug formulation |
| WO2017070462A1 (en) * | 2015-10-21 | 2017-04-27 | Nova Southeastern University | Compositions for deterring abuse of pharmaceutical products and alcohol |
| EP3210596A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical composition |
| EP3231420A1 (en) | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| EP3210630A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| WO2017192608A1 (en) * | 2016-05-03 | 2017-11-09 | Kashiv Pharma Llc | Immediate release drug formulation combining opioid and nonopioid analgesics with abuse deterrence and overdose protection |
| EP3641734A4 (en) * | 2017-06-23 | 2021-03-17 | Sun Pharma Advanced Research Company Limited | ANTI-ABUSE ORAL SOLID DOSAGE FORM |
| WO2019126125A1 (en) | 2017-12-20 | 2019-06-27 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
| US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
| US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| US6696088B2 (en) | 2000-02-08 | 2004-02-24 | Euro-Celtique, S.A. | Tamper-resistant oral opioid agonist formulations |
| JP2005501067A (ja) * | 2001-08-06 | 2005-01-13 | ユーロ−セルティーク，エス．エイ． | オピオイドの乱用を防ぐための組成物および方法 |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| IL160217A0 (en) * | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Compositions and methods to prevent abuse of opioids |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
| ATE425744T1 (de) * | 2002-04-29 | 2009-04-15 | Supernus Pharmaceuticals Inc | Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit |
| HUE038446T2 (hu) * | 2002-09-20 | 2018-10-29 | Alpharma Pharmaceuticals Llc | Szekvesztráló alegység és releváns kompozíciók és módszerek |
| DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| DK1765292T3 (en) | 2004-06-12 | 2018-01-02 | Collegium Pharmaceutical Inc | ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS |
| US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| FR2892937B1 (fr) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
| US8652529B2 (en) * | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US8460640B2 (en) * | 2008-12-12 | 2013-06-11 | Paladin Labs, Inc. | Narcotic drug formulations with decreased abuse potential |
-
2012
- 2012-02-17 US US13/400,004 patent/US20120321716A1/en not_active Abandoned
- 2012-02-17 EP EP12712786.8A patent/EP2675436A1/en not_active Withdrawn
- 2012-02-17 BR BR112013021026A patent/BR112013021026A2/pt not_active IP Right Cessation
- 2012-02-17 JP JP2013554661A patent/JP2014505736A/ja active Pending
- 2012-02-17 CN CN2012800187591A patent/CN103476401A/zh active Pending
- 2012-02-17 AU AU2012219322A patent/AU2012219322A1/en not_active Abandoned
- 2012-02-17 MX MX2013009492A patent/MX2013009492A/es not_active Application Discontinuation
- 2012-02-17 WO PCT/US2012/025737 patent/WO2012112952A1/en not_active Ceased
- 2012-02-17 CA CA2827273A patent/CA2827273A1/en not_active Abandoned
-
2013
- 2013-08-14 IL IL227962A patent/IL227962A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505736A5 (cg-RX-API-DMAC7.html) | ||
| JP5937068B2 (ja) | 転用防止微粒剤および微小錠剤 | |
| ES2582453T3 (es) | Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada | |
| KR101424653B1 (ko) | 에탄올의 영향에 대하여 내성을 가지는 ｐｈ-의존성 조절 방출 제약학적 오피오이드 조성물 | |
| JP5167345B2 (ja) | 薬剤を加速放出する腸溶コーティングを含む固体剤形 | |
| CA2661561C (en) | Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water | |
| JP2018517676A5 (cg-RX-API-DMAC7.html) | ||
| RU2009111588A (ru) | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств | |
| TW200934532A (en) | Misuse preventative, controlled release formulation | |
| PT1830855E (pt) | Formas de apresentação farmacêuticas sólidas, para administração oral, contendo ritaroxaban com libertação modificada | |
| JP2012503608A (ja) | エタノールの影響に対する耐性を有するｐＨ依存の制御放出の医薬オピオイド組成物 | |
| US20130084333A1 (en) | Abuse resistant oral dosage forms | |
| JP2016539953A5 (cg-RX-API-DMAC7.html) | ||
| CN107106503B (zh) | 抗滥用药物组合物 | |
| CN104540499A (zh) | 含有药物的中空颗粒 | |
| JP2008522989A5 (cg-RX-API-DMAC7.html) | ||
| JP2005306778A (ja) | 徐放性製剤及びその製造方法 | |
| CN103006661A (zh) | 一种含有盐酸鲁拉西酮的制剂及其制备方法 | |
| EP1502587B1 (en) | Sustained release formulation for Venlafaxine hydrochloride | |
| CN102178657A (zh) | 一种新型的奥氮平口腔崩解片 | |
| WO2012029838A1 (ja) | 口腔内崩壊錠 | |
| JP2019513801A5 (cg-RX-API-DMAC7.html) | ||
| US20140127294A1 (en) | Oral solid formulation of compound anti-tubercular drug and preparation method thereof | |
| CN101347413A (zh) | 喹硫平缓释片及其制备方法 | |
| JP5443768B2 (ja) | 医薬品球状物 |